Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 5.9% in November

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 168,800 shares, a decline of 5.9% from the October 31st total of 179,400 shares. Currently, 18.0% of the company’s stock are sold short. Based on an average daily trading volume, of 589,300 shares, the days-to-cover ratio is currently 0.3 days.

Allarity Therapeutics Stock Down 1.9 %

Shares of ALLR opened at $1.06 on Wednesday. The firm’s 50 day moving average price is $1.49 and its 200 day moving average price is $5.75. Allarity Therapeutics has a twelve month low of $1.04 and a twelve month high of $666.00.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.